Pharmacology of the class 111 antiarrhythmic agent sematilide in patients with arrhythmias

Wilson Wong, Harris N. Paviou, Ulrika M. Birgersdotter, Daniel E. Hillernan, Syed M. Mohiuddin, Dan M. Roden

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Sematilide, a close structural analog of N-acetylprocainamide, prolongs cardiac action potentials in vitro, whereas it does not depress maximum action potential upstroke slope, a "class III" action. This report outlines an evaluation of the clinical pharmacologic actions of sematilide in 14 patients with chronic high-frequency nonsustained ventricular arrhythmias. In all, 36 intravenous infusions (range 0.15 to 1.5 mg/kg over 15 minutes) were administered in a dose-ranging, placebo-controlled study design. Sematilide prolonged rate-corrected QT (QTc) in a dose- and concentration-related fashion, did not alter PR or QRS, and slowed heart rate at high concentrations (≥2 μg/ml). The relations between dose and total area under the time-concentration curve, dose and peak plasma concentration, and peak plasma concentration and increase in QTc were linear (r = 0.66 to 0.92; p

Original languageEnglish
Pages (from-to)206-212
Number of pages7
JournalAmerican Journal of Cardiology
Volume69
Issue number3
DOIs
StatePublished - Jan 15 1992

Fingerprint

Cardiac Arrhythmias
Pharmacology
Action Potentials
Acecainide
Pharmacologic Actions
Intravenous Infusions
Heart Rate
Placebos
sematilide
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacology of the class 111 antiarrhythmic agent sematilide in patients with arrhythmias. / Wong, Wilson; Paviou, Harris N.; Birgersdotter, Ulrika M.; Hillernan, Daniel E.; Mohiuddin, Syed M.; Roden, Dan M.

In: American Journal of Cardiology, Vol. 69, No. 3, 15.01.1992, p. 206-212.

Research output: Contribution to journalArticle

Wong, Wilson ; Paviou, Harris N. ; Birgersdotter, Ulrika M. ; Hillernan, Daniel E. ; Mohiuddin, Syed M. ; Roden, Dan M. / Pharmacology of the class 111 antiarrhythmic agent sematilide in patients with arrhythmias. In: American Journal of Cardiology. 1992 ; Vol. 69, No. 3. pp. 206-212.
@article{69266277302f429a8670b90429dbc490,
title = "Pharmacology of the class 111 antiarrhythmic agent sematilide in patients with arrhythmias",
abstract = "Sematilide, a close structural analog of N-acetylprocainamide, prolongs cardiac action potentials in vitro, whereas it does not depress maximum action potential upstroke slope, a {"}class III{"} action. This report outlines an evaluation of the clinical pharmacologic actions of sematilide in 14 patients with chronic high-frequency nonsustained ventricular arrhythmias. In all, 36 intravenous infusions (range 0.15 to 1.5 mg/kg over 15 minutes) were administered in a dose-ranging, placebo-controlled study design. Sematilide prolonged rate-corrected QT (QTc) in a dose- and concentration-related fashion, did not alter PR or QRS, and slowed heart rate at high concentrations (≥2 μg/ml). The relations between dose and total area under the time-concentration curve, dose and peak plasma concentration, and peak plasma concentration and increase in QTc were linear (r = 0.66 to 0.92; p",
author = "Wilson Wong and Paviou, {Harris N.} and Birgersdotter, {Ulrika M.} and Hillernan, {Daniel E.} and Mohiuddin, {Syed M.} and Roden, {Dan M.}",
year = "1992",
month = "1",
day = "15",
doi = "10.1016/0002-9149(92)91306-O",
language = "English",
volume = "69",
pages = "206--212",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Pharmacology of the class 111 antiarrhythmic agent sematilide in patients with arrhythmias

AU - Wong, Wilson

AU - Paviou, Harris N.

AU - Birgersdotter, Ulrika M.

AU - Hillernan, Daniel E.

AU - Mohiuddin, Syed M.

AU - Roden, Dan M.

PY - 1992/1/15

Y1 - 1992/1/15

N2 - Sematilide, a close structural analog of N-acetylprocainamide, prolongs cardiac action potentials in vitro, whereas it does not depress maximum action potential upstroke slope, a "class III" action. This report outlines an evaluation of the clinical pharmacologic actions of sematilide in 14 patients with chronic high-frequency nonsustained ventricular arrhythmias. In all, 36 intravenous infusions (range 0.15 to 1.5 mg/kg over 15 minutes) were administered in a dose-ranging, placebo-controlled study design. Sematilide prolonged rate-corrected QT (QTc) in a dose- and concentration-related fashion, did not alter PR or QRS, and slowed heart rate at high concentrations (≥2 μg/ml). The relations between dose and total area under the time-concentration curve, dose and peak plasma concentration, and peak plasma concentration and increase in QTc were linear (r = 0.66 to 0.92; p

AB - Sematilide, a close structural analog of N-acetylprocainamide, prolongs cardiac action potentials in vitro, whereas it does not depress maximum action potential upstroke slope, a "class III" action. This report outlines an evaluation of the clinical pharmacologic actions of sematilide in 14 patients with chronic high-frequency nonsustained ventricular arrhythmias. In all, 36 intravenous infusions (range 0.15 to 1.5 mg/kg over 15 minutes) were administered in a dose-ranging, placebo-controlled study design. Sematilide prolonged rate-corrected QT (QTc) in a dose- and concentration-related fashion, did not alter PR or QRS, and slowed heart rate at high concentrations (≥2 μg/ml). The relations between dose and total area under the time-concentration curve, dose and peak plasma concentration, and peak plasma concentration and increase in QTc were linear (r = 0.66 to 0.92; p

UR - http://www.scopus.com/inward/record.url?scp=0026593345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026593345&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(92)91306-O

DO - 10.1016/0002-9149(92)91306-O

M3 - Article

VL - 69

SP - 206

EP - 212

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -